Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Apr 15;27(8):1705-1708.
doi: 10.1016/j.bmcl.2017.02.080. Epub 2017 Mar 4.

Substrate and Inhibitor Specificity of Kynurenine Monooxygenase From Cytophaga Hutchinsonii

Affiliations

Substrate and Inhibitor Specificity of Kynurenine Monooxygenase From Cytophaga Hutchinsonii

Robert S Phillips et al. Bioorg Med Chem Lett. .

Abstract

Kynurenine monooxygenase (KMO) is a potential drug target for treatment of neurodegenerative disorders such as Huntington's and Alzheimer's diseases. We have evaluated substituted kynurenines as substrates or inhibitors of KMO from Cytophaga hutchinsonii. Kynurenines substituted with a halogen at the 5-position are excellent substrates, with values of kcat and kcat/Km comparable to or higher than kynurenine. However, kynurenines substituted in the 3-position are competitive inhibitors, with KI values lower than the Km for kynurenine. Bromination also enhances inhibition, and 3,5-dibromokynurenine is a potent competitive inhibitor with a KI value of 1.5μM. A pharmacophore model of KMO was developed, and predicted that 3,4-dichlorohippuric acid would be an inhibitor. The KI for this compound was found to be 34μM, thus validating the pharmacophore model. We are using these results and our model to design more potent inhibitors of KMO.

Keywords: Drug target; Kynurenine analogue; Neurodegenerative diseases; Pharmacophore model.

Similar articles

See all similar articles

Cited by 3 articles

MeSH terms

LinkOut - more resources

Feedback